Skip to main content

Novartis hemoglobinuria trial meets two primary endpoints

The trial studied a drug named Iptacopan and established its superiority to a previously used treatment in helping patients with debilitating anemia.
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.